Skip to main content
. 2016 Feb 24;84(3):782–789. doi: 10.1128/IAI.01268-15

FIG 2.

FIG 2

Therapeutic effect of recombinant IL-22 in K. pneumoniae peritonitis. (A) Schema of recombinant IL-22 (rIL-22) treatment model. K. pneumoniae-infected WT mice were treated i.p. with rIL-22 after 2 h of K. pneumoniae infection. After 20 h of K. pneumoniae infection, the mice were sacrificed and tissues were collected. (B) K. pneumoniae burdens in liver tissue homogenates. (C) ALT levels in serum. (D and E) Representative liver histology as shown by H&E staining (D), and liver injury scores (E). Original magnification, ×4 for left panel and ×20 for right panel and images used to determine the liver injury scores in panel E. (F) Serum bacteriostatic activity against K. pneumoniae in vitro. The sera were from the experimental mice as described in the schema in panel A. Each line represents different conditions, as follows: a, K. pneumoniae growth in medium only; b, K. pneumoniae growth in naive serum; c, K. pneumoniae growth in serum from rIL-22-treated mice; d, K. pneumoniae growth in serum from K. pneumoniae-challenged and rIL-22-treated mice; e, K. pneumoniae growth in serum from K. pneumoniae-challenged mice. These data were analyzed by two-way ANOVA for multiple comparison with Tukey's test (34). All values represent the mean results ± SD (n = 4 to 10 replicates). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.